Quarterly ResultMay 11, 2026, 04:03 PM
Erasca's ERAS-0015 Shows Robust Efficacy; $409M Cash Funds into H2 2028
AI Summary
Erasca, Inc. reported Q1 2026 financial results and provided business updates, highlighting robust monotherapy efficacy and favorable safety for ERAS-0015 in KRAS G12X NSCLC and PDAC. The company entered into clinical trial collaborations with Merck and Tango Therapeutics for ERAS-0015 combinations and expanded its license agreement for ERAS-0015 to worldwide rights. Erasca also reported a strong cash position of $408.5 million, expected to fund operations into the second half of 2028, following a successful $258.8 million public offering in January 2026. Preliminary data for ERAS-4001 is expected in H2 2026.
Key Highlights
- ERAS-0015 showed robust monotherapy efficacy and favorable safety in KRAS G12X NSCLC and PDAC.
- Cash, cash equivalents, and marketable securities totaled $408.5 million as of March 31, 2026.
- Cash position is expected to fund operations into the second half of 2028.
- Entered CTCSA with Merck for ERAS-0015 + KEYTRUDA and with Tango for ERAS-0015 + vopimetostat.
- Expanded ERAS-0015 license to worldwide rights, incurring $150.0 million in-process R&D expense.
- Net loss for Q1 2026 was $183.4 million, or $(0.60) per share.
- Preliminary monotherapy data for ERAS-4001 expected in H2 2026.
- Completed $258.8 million public offering in January 2026.